About Clementia
Clementia is a Healthcare company based in Dorval (Canada) founded in 2012, and was acquired by Ipsen in February 2019. Small Molecule to treat rare bone diseases such as Fibrodysplasia Ossificans Progressiva (FOP). Clementia has raised $92.5 million across 5 funding rounds from investors including UCB, Ipsen and Orbimed. Its chief executive, as recorded, is David Loew. Clementia offers products and services including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its legal entity is Ipsen Pharma.
Company details
Clementia was founded in 2012 in Dorval, Canada, within the biotechnology sector focused on rare diseases. Treatments for conditions like Fibrodysplasia Ossificans Progressiva are advanced through retinoic acid receptor gamma science. The lead candidate, Palovarotene, is investigated as an agonist to inhibit abnormal bone growth. Orphan Drug Designation was granted by the FDA in 2014, and Orphan Medicinal Product Designation was received from the EMA.
Products & Services of Clementia
Clementia offers a comprehensive portfolio of products and services, including Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Treatments for cancers and tumors in oncology field
Therapies for rare genetic and liver disorders
Medications for debilitating neurological conditions
Apps and channels of Clementia
its YouTube channel Ipsen has 1.05K subscribers and 30 videos.
Videos from Clementia
The most watched videos on Clementia's YouTube channel, Ipsen (1.05K subscribers). Click a video to play it here.
More on Ipsen.
Funding Insights of Clementia
Clementia has successfully raised a total of $92.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $60 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92.5M
- Total Rounds 5
- Last Round Series B — $60M
- Investors Count 8
All 5 funding rounds of Clementia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
9 investors in total: 9 institutional.
Investors in Clementia
Clementia has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include UCB, Ipsen and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
| ecor1cap.com | ||||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Therapies for immunological and neurological disorders are developed. | 1928 | ucb.com | Brussels, Belgium | |
Commercial banking services for small and medium-sized enterprises are provided. | 1944 | bdc.ca | Montreal, Canada | |
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | 1929 | ipsen.com |
Investor details for Clementia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Clementia
738 people are tracked at Clementia (380 in leadership, 13 in board & advisors, 345 in team).
| Name | Role | Group |
|---|---|---|
David Loew | CEO | Leadership |
Aurélien Biechy | Senior Director IP | Leadership |
Dr Fiona Maxwell | Vice President, Head Of Early Stage Clinical Development | Leadership |
Luis Zuniga Dnp | Regional Field Medical Director | Leadership |
Yu Fu | Medical Information Director | Leadership |
Torianio White | Director Medical Affairs Training | Leadership |
Caroline Boin-Margerit | VP Corporate Communications | Leadership |
David Gruber | Senior Director Of Bioprocess Development (usp & Dsp) | Leadership |
Helene. Mathiex-Fortunet | Vice President Drugdevelopment- Primary Careproducts | Leadership |
Karen Martin | Svp, Chief IP Counsel | Leadership |
Stéphane Masseran | SVP & Chief Procurement Officer; Head Of Global Real Estate | Leadership |
Vincent Berny | Head Of Global Product Quality | Leadership |
Jennifer Glennon | Senior Vice President, Global Portfolio Operations | Leadership |
Yacoub Adjibade | Vice President | Leadership |
Chris Watters | Ad Interim Senior Vice President, Franchise Head, Oncology Business Unit | Leadership |
Sarah O'Mahony | Global Head Of Asset Operations Neuroscience | Leadership |
Sarah Desi Arragon | Senior Director, Strategic Alliance Management | Leadership |
Josep Catllà | EVP & Chief Corporate Affairs Officer | Leadership |
Anne-Sophie Dubromer | Global Digital Transformation And Communication Director | Leadership |
Jean-Francois Muller | Vice President Procurement Americas | Leadership |
718 more people are available in the full profile.
Complete people profiles for Clementia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Clementia
5 dated milestones of Clementia across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Clementia is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $60.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Ipsen.
Web traffic of Clementia
Websites that share an audience with Clementia (clementiapharma.com).
Websites whose visitors overlap most with Clementia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| acurapharm.com | 100% | 2.4K | #8,922,263 | View details | |
img.medscape.com | img.medscape.com | 77% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Clementia
Complete news archive for Clementia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Clementia
Clementia was founded in 2012.
Clementia is headquartered in Dorval, Canada. It is registered at Dorval, Quebec, Canada.
David Loew is the CEO of Clementia, as recorded in our data.
Clementia is a funded company, having raised a total of $92.5M across 5 funding rounds to date.
Clementia was founded in 2012 in Dorval, Canada, within the biotechnology sector focused on rare diseases. Treatments for conditions like Fibrodysplasia Ossificans Progressiva are advanced through retinoic acid receptor gamma science. The lead candidate, Palovarotene, is investigated as an agonist to inhibit abnormal bone growth. Orphan Drug Designation was granted by the FDA in 2014, and Orphan Medicinal Product Designation was received from the EMA.
Clementia offers Oncology Medicines, Rare Disease Treatments, and Neuroscience Products.
Clementia has 9 investors. Key investors include UCB, Ipsen, Orbimed, Janus Henderson Investors, and RA Capital.
Clementia operates through Ipsen Pharma.
Yes. Clementia was acquired by Ipsen in February 2019.